Dr. Mantsch received his Ph.D. in pharmacology from Louisiana State University and post-doctoral training in the Laboratory of the Biology of Addictive Diseases at the Rockefeller University prior to joining the faculty in the Department of Biomedical Sciences in 2001. He is currently the Chair of the Department. Dr. Mantsch’s research involves the preclinical study of neuropsychiatric disease with a focus on understanding the neurobiological underpinnings of addiction. He receives funding for his research from the National Institute on Drug Abuse and the National Center on Complementary and Alternative Medicine. Dr. Mantsch is also involved in CNS medication development and is a co-founder of Promentis Pharmaceuticals, a start-up pharmaceutical company that originated in the Department of Biomedical Sciences at Marquette.
Dr. Mantsch is the Course Director for BISC 7520 and 7120, professional level dental and medical pharmacology courses, and teaches in the undergraduate BISC 4120 pharmacology course as well a various graduate-level neurosciences classes. He participates in the Neuroscience Graduate Program and currently serves as a dissertation advisor for three doctoral students. Dr. Mantsch is also the Director of the College of Health Sciences Summer Research Program for undergraduate students and has served as a research mentor for more than 50 undergraduate students since his arrival at Marquette.
Understanding of the neurobiological basis of CNS disease to develop new and more effective treatment strategies.
Current research in my laboratory focuses on exploring the relationship between stress and drug addiction, identifying the neurobiological mechanisms underlying drug craving and relapse, and developing new medications for the management of addiction and other neuropsychiatric conditions. Specific projects include the study of addiction-related glucocorticoid-dependent neuroplasticity in stress and reward systems, determination of the role of CRF, noradrenergic, and dopaminergic signaling in stress-induced relapse, examination of the impact of chronic stress on addiction and depression, and investigation of the potential utility of plant-derived tetrahydroprotoberberine compounds (e.g., levo-tetrahydropalmatine) and novel cysteine prodrugs for the treatment of addiction.